Genomma Lab Internacional. de (GNML.F) Stock Overview
Provides pharmaceutical and personal care products primarily in Mexico and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
GNML.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Genomma Lab Internacional, S.A.B. de C.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Mex$0.96 |
| 52 Week High | Mex$1.43 |
| 52 Week Low | Mex$0.93 |
| Beta | 0.36 |
| 1 Month Change | 2.46% |
| 3 Month Change | n/a |
| 1 Year Change | -24.88% |
| 3 Year Change | 23.37% |
| 5 Year Change | 8.84% |
| Change since IPO | -50.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| GNML.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.8% | 4.9% | -2.7% |
| 1Y | -24.9% | 20.3% | 11.9% |
Return vs Industry: GNML.F underperformed the US Pharmaceuticals industry which returned 19.1% over the past year.
Return vs Market: GNML.F underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| GNML.F volatility | |
|---|---|
| GNML.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GNML.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GNML.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,708 | Juan Marco Sparvieri | www.genommalab.com |
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary
| GNML.F fundamental statistics | |
|---|---|
| Market cap | US$932.27m |
| Earnings (TTM) | US$89.81m |
| Revenue (TTM) | US$987.02m |
Is GNML.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNML.F income statement (TTM) | |
|---|---|
| Revenue | Mex$18.19b |
| Cost of Revenue | Mex$6.68b |
| Gross Profit | Mex$11.51b |
| Other Expenses | Mex$9.86b |
| Earnings | Mex$1.66b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.69 |
| Gross Margin | 63.30% |
| Net Profit Margin | 9.10% |
| Debt/Equity Ratio | 66.7% |
How did GNML.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 21:57 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genomma Lab Internacional, S.A.B. de C.V. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Antonio Hernandez Velez Leija | Actinver Case de Bolsa, S.A. de C.V. |
| Benjamin Theurer | Barclays |
| Robert Ford Aguilar | BofA Global Research |